Zontivity’s Small Effect On Absolute Risk Reflects Advances In Therapy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Zontivity NDA offered a rare chance to assess absolute, as opposed to relative, risk because it was tested against placebo – the drug is positioned to be a new, third prong to antiplatelet therapy. ODE I Director Ellis Unger discussed the “seemingly small reduction in absolute risk” in the context of medical advances that have made CV events in the secondary prevention setting less common overall.